Median overall survival was significantly longer in the vemurafenib group than in the dacarbazine group ( 136 months [ 95 % CI 120-152 ] vs 97 months [ 79-128 ] ; hazard ratio [ HR ] 070 [ 95 % CI 057-087 ] ; p = 00008 ) , as was median progression-free survival ( 69 months [ 95 % CI 61-70 ] vs 16 months [ 16-21 ] ; HR 038 [ 95 % CI 032-046 ] ; p < 00001 ) .